Treatment with CAR T-cell and bispecific therapies is a labor-intensive process and requires substantial interprofessional collaboration. Additional education and training of all involved clinical staff is essential to managing these patients as well as their subsequent toxicities.

With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients.

Live satellite symposium with a panel of experts discussing current guidelines and latest clinical evidence for the management of patients with multiple myeloma including expert guidance to help inform treatment decisions and therapy sequencing.

With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.

The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as well as previously treated MM included in Version 1.2025 of the NCCN Guidelines for MM.

With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.